Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai, Jamaica, NY, USA.
Rajshekhar
R
Chakraborty
Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai, Jamaica, NY, USA.
Shiva Kumar Reddy
SK
Mukkamalla
Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai, Jamaica, NY, USA.
Kranthi
K
Singam
Department of Internal Medicine, Queens Hospital Center, Icahn School of Medicine at Mount Sinai, Jamaica, NY, USA.
Natalia
N
Calderon
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002872:Chromosome Deletion; D002899:Chromosomes, Human, Pair 9; D020732:Cytogenetic Analysis; D004252:DNA Mutational Analysis; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D033162:Incidental Findings; D007713:Klinefelter Syndrome / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl